This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO 2019 Congress

ESMO 2019 Congress

At the ESMO 2019 Congress, Boehringer Ingelheim hosted a symposium on treatment decisions for advanced non-small cell lung cancer (NSCLC), as well as presenting data highlighting recent findings in the treatment of lung cancer.

27 September–1 October 2019
Fira Gran Via, Barcelona, Spain

Symposium: Making first- and second-line treatment decisions for advanced NSCLC

At this symposium, an international faculty of experts discussed first-line treatment decisions for EGFR mutation-positive NSCLC and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-oncogene addicted, non-squamous disease. Please see below for presentation downloads.

        James Yang, National Taiwan University

Chair; moderator of Q&A sessions; Common options for uncommon mutations

Presenter(s): James Yang, National Taiwan University
        Barbara Melosky, University of British Columbia

Sequencing to prolong the chemotherapy-free period

Presenter(s): Barbara Melosky, University of British Columbia
        Noemi Reguart, Hospital Clinic Barcelona

Squamous NSCLC: where do EGFR TKIs fit in?

Presenter(s): Noemi Reguart, Hospital Clinic Barcelona
        Maximilian Hochmair, Otto Wagner Hospital

Non-mutated, non-squamous NSCLC (adenocarcinoma): failing first-line immunotherapy + chemotherapy, what now?

Presenter(s): Maximilian Hochmair, Otto Wagner Hospital

Publications

We also presented a number of publications during the scientific programme at ESMO – please see downloadable versions below.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Saturday 28th September 2019
Afatinib* followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Author(s): Hochmair et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1532P
Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Author(s): de Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1472P
A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Author(s): de Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1474P
Efficacy and safety of nintedanib** + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing noninterventional study (NIS) VARGADO (NCT02392455)
Author(s): Grohé et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1505P
Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Author(s): Girard et al.
Poster Presentation
Tumour Type(s): Solid tumours
Presentation Number: 1593TiP
There are no publications which meet your criteria on this date
Monday 30th September 2019
Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Author(s): Liu et al.
Poster Presentation
Tumour Type(s): Multiple tumours
Presentation Number: 1969P
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: September 2019